Drug Database
SU

sumatriptan succinate (Zelrix / NP101 / Zecuity)

✓ Approved

Nupathe Inc. · HTR1D · 小分子

什么是 sumatriptan succinate?

sumatriptan succinate 是一种小分子,由Nupathe Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Topical、Transdermal。

药物档案

商品名Zelrix, NP101, Zecuity
公司Nupathe Inc.
药物类别小分子
分子靶点HTR1D
给药途径Topical, Transdermal
状态Approved

作用机制

分子靶点

sumatriptan succinate 作用于 1 个分子靶点:

HTR1D5-hydroxytryptamine receptor 1D (HTR1DA, HT1DA)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

sumatriptan succinate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersMigraine✓ Approved

相关研究文献

PubMedZhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]2026-07-27

[Research progress of gut microbial metabolite succinate in inflammatory diseases].

Chen Y X YX, Niu M M, Du Y Y

Inflammatory diseases are pathological conditions precipitated by inflammation, with the gut microbiota and its metabolites playing a pivotal role in the inflammatory process. Succinate, a key metabolite generated by gut microorganisms, is implicated not only in the energy metabolism of the tricarboxylic acid cycle but also in the modulation of inflammatory processes via the succinate receptor 1-mediated immune regulatory pathway. This review provides a unified elaboration on the metabolic pathways and biological characteristics of succinate, the detection techniques for succinate, and the potential applications of succinate in the diagnosis and treatment of inflammatory diseases, aiming to provide a scientific basis for the development of relevant diagnosis and treatment strategies.

PMID 42503938
阅读全文 →
PubMedMolecular pharmaceutics2026-07-27

Correction to "d-α-Tocopherol Polyethylene Glycol Succinate-Based Redox-Sensitive Paclitaxel Prodrug for Overcoming Multidrug Resistance in Cancer Cells".

Bao Yuling Y, Guo Yuanyuan Y, Zhuang Xiangting X, Li Dan D et al.

PMID 42505427
阅读全文 →
PubMedMetabolites2026-07-27

Integrated Multi-Omics Links Bisphenol AF (BPAF) Exposure to Hepatic Lipid Metabolism Disruption via Succinate Dehydrogenase Dysfunction and Mitochondrial Impairment.

Wang Ning N, Xu Jing J, Leng Jing J, Xu Jia-Le JL et al.

Background/Objective: Bisphenol AF (BPAF), a fluorinated analogue of bisphenol A, is an environmental contaminant associated with hepatotoxicity and metabolic disruption. However, the systematic molecular mechanisms linking early transcriptional events to metabolic dysfunction in the liver remain poorly defined. The aim of this study is to elucidate the association between BPAF exposure and hepatic lipid accumulation by integrating transcriptomics, cellular metabolomics, and targeted phenotypic assays. Methods: We performed RNA-sequencing on livers from mice exposed to BPAF (0.1-10 mg/kg/day, 28 days), and performed non-targeted metabolomics on AML12 murine hepatocytes co-cultured with RAW264.7 macrophages in a Transwell system (0-2500 nM BPAF, 48 h). Key metabolic pathways were identified through integrated bioinformatics and validated using enzymatic assays, qRT-PCR, Western blotting, and phenotypic staining (lipid droplets, ROS). Results: Multi-omics integration revealed significant disruption of PPAR signaling and the tricarboxylic acid (TCA) cycle. A striking dose-dependent accumulation of succinate was observed in exposed cells, concomitant with a significant inhibition of succinate dehydrogenase (SDH) activity (52% reduction at 2500 nM, p < 0.001). Transcriptomic data confirmed the downregulation of mitochondrial fatty acid β-oxidation genes. Phenotypic validation indicated that BPAF exposure is associated with oxidative stress, pro-inflammatory cytokine release (TNF-α, IL-6), and pronounced intracellular lipid droplet accumulation in hepatocytes. Conclusions: This study suggests that BPAF exposure is associated with SDH dysfunction, TCA cycle arrest, and lipid dysregulation. Whether BPAF directly inhibits SDH or acts through upstream mitochondrial targets warrants further structural and kinetic investigation.

PMID 42506394
阅读全文 →
PubMedPhysiological reports2026-07-27

Fiber type specific tibialis anterior muscle atrophy and oxidative capacity reduction is contemporaneous with death of larger lumbar motor neurons in old rats.

Rooker Kathryn D KD, Hernandez-Vizcarrondo Genesis A GA, Cheung Sang Won SW, Mahadev Bhat Sanjana S et al.

Age-associated muscle weakness and atrophy of limb muscles, termed sarcopenia, is a major factor in the morbidity of the elderly. It is becoming increasingly recognized that a substantial contribution to the sarcopenic phenotype arises from motor neuron (MN) death in old age and subsequent muscle denervation. In human and rodent models, mitochondrial dysfunction is a leading culprit in both muscle and MN deterioration with age. In other motor pools within the Fischer 344 (F344) aging rat model, we showed that sarcopenia is selective to type IIx/b muscle fibers. We also showed a loss of larger MNs and denervation of the IIx/b fibers, which together comprise more fatigable fast (type FF) motor units. This selective vulnerability of larger MNs and type IIx/b muscle fibers to sarcopenia is further reflected by reductions in oxidative capacity of IIx/b fibers, as assayed by determining the maximum velocity of the succinate dehydrogenase reaction (SDHmax). Here, we hypothesize similar changes will occur in F344 tibialis anterior (TA) muscle from young (6-months) and old (24-months) groups. We also predict lumbar MN death in young and old F344 rats. We found selective atrophy of type IIx/b fibers in the TA from old rats. In old age, SDHmax was reduced but only in IIx/b TA fibers. These muscle observations were concomitant with the death of larger lumbar MNs in old age. This study indicates the remarkable selectivity of type FF TA motor units to age-associated perturbations and sarcopenia.

PMID 42503696
阅读全文 →
PubMedDrug development and industrial pharmacy2026-07-27

Tumor microenvironment improved by nanostructured lipid carriers co-deliverying paclitaxel and ubenimex to treat breast cancer.

Xia Shuai S, Sheng Tao T, Li Jia-Min JM, Zhang Bing-Feng BF et al.

The aim of this research was to design nanostructured lipid carriers co-delivering paclitaxel and ubenimex to improve the tumor microenvironment and enhance efficacy against breast cancer. Nanostructured lipid carriers (NLC) offer unique advantages for co-delivery of anti-tumor drugs, including high drug-loading capacity, controlled-release performance, and facile functionalization. This study developed a nanostructured lipid carrier (NLC) co-loaded with paclitaxel and ubenimex to achieve synergistic therapeutic effects on breast cancer by improving the immunosuppressive tumor microenvironment. Ubenimex (Uben) was conjugated to vitamin E polyethylene glycol succinate (TPGS) via ester bonds, after which the synthetic conjugate, paclitaxel, and lipid materials were formulated into the nanostructured lipid carrier (PTX/Uben-NLC) by the emulsified solvent evaporation-low-temperature curing method and subsequently characterized and evaluated for improved anti-tumor efficacy. The prepared PTX/Uben-NLC was approximately spherical with a negative potential and a particle size of about 161 nm. The formulation demonstrated sustained drug release. Uben exhibited pH-responsive release in the weakly acidic tumor microenvironment (TME) and induced immune cell activation and secretion of anti-tumor cytokines (IFN-γ, TNF-α, IL-12), while secretion of immunosuppressive cytokines (TGF-β and IL-10) was concurrently inhibited. PTX exerted direct anti-tumor effects on tumor cells. Consequently, the PTX/Uben-NLC alleviated TME immunosuppression and enhanced anti-breast-cancer activity. Dual-drug-loaded nanostructured lipid carriers alleviated TME immunosuppression to enhance synergistic anti-breast cancer therapy and provided a feasible solution for breast cancer treatment.

PMID 42505014
阅读全文 →
PubMedJournal of pharmaceutical analysis2026-07-26

Drug delivery system of curcumin to the lungs based on poly(3-alloxyloxy-1,2-propylene succinate)-sebacic acid copolymers.

Knap Karolina K, Kwiecień Konrad K, Czajkowski Jonasz J, Szostecki Rafał R et al.

Polyanhydrides are attractive materials for drug delivery matrices as a result of their cytocompatibility and fast degradation rate. Here, we synthesized and characterized copolymers of poly(3-allyloxy-1,2-propylene succinate) (PSAGE) and sebacic acid (SBA). The successful polymerization was confirmed by proton nuclear magnetic resonance (1H NMR) and Fourier transform infrared (FTIR) spectroscopy analyses. The material with PSAGE and 60% of SBA copolymer (PSAGE-SBA60) was more hydrophilic than the PSAGE and 80% of SBA copolymer (PSAGE-SBA80) (water contact angle 82.2° ± 11.6° vs. 98.6° ± 8.9°, respectively). PSAGE-SBA60 also had a lower molecular weight than PSAGE-SBA80 (Mn = 6400 Da vs. 9800 Da). Both polyanhydrides were used to encapsulate curcumin (CUR) as a potential anti-inflammatory, antimicrobial and anticancer agent. The unloaded microparticles (MPs) and CUR-loaded MPs were produced using the emulsification/solvent evaporation method. The CUR was uniformly distributed within the MPs, as confirmed by fluorescence microscopy. All MPs had a geometric diameter < 5 μm and their surface charge was negative. MPs_PSAGE-SBA80 + CUR had the best aerodynamic properties, as shown by laser diffraction measurements and flowability parameters, i.e., Carr index and Hausner ratio. The MPs obtained from PSAGE-SBA60 degraded faster than those of PSAGE-SBA80. All MPs were noncytotoxic at a concentration of up to 100 μg/mL in the in vitro model (BEAS-2B lung epithelial cells) and ex vivo precision-cut tissue slices (PCTSs) rat model. The developed MPs are promising CUR carriers for pulmonary delivery in a dry powder formulation.

PMID 42502720
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多sumatriptan succinate